Across 123 CTIS prostate cancer Phase II/III geography records, activity is balanced between Phase II and Phase III, with Phase III representing 64 records and Phase II representing 59 records. The strongest recurring EU site networks are concentrated in Spain, France, Italy, and Germany, with Vall d’Hebron, Institut de Cancerologie de l’Ouest, Hospital Clinic de Barcelona, Istituto Oncologico Veneto, Centre Leon Berard, and Universitaetsklinikum Essen appearing as key recurring prostate trial anchors.
The dataset contains 123 Phase II/III prostate cancer geography records. Phase III accounts for 64/123 records, or 52.0%, while Phase II accounts for 59/123 records, or 48.0%. This indicates a mature development landscape where confirmatory programs slightly outnumber mid-stage expansion and signal-finding studies.
The near-even Phase II/III split suggests prostate cancer remains both an active late-stage registration area and a continuing expansion space for new modalities, combinations, and disease-stage positioning.
Most prostate cancer Phase II/III geography activity is concentrated in 2024. Across 123 records, 76 were authorized in 2024, representing 61.8%; 38 were authorized in 2025, representing 30.9%; and 9 were authorized in 2026, representing 7.3%.
The 2024-heavy distribution indicates that the observed prostate trial site network is shaped primarily by recently authorized, but not exclusively current-year, programs. The 2026 slice should be read as an early-year signal rather than a mature full-year comparison.
The most recurrent site network is concentrated around major prostate oncology, urology, radiotherapy, and nuclear medicine centers. The top 10 recurring named EU sites are led by Hospital Universitari Vall d’Hebron, Institut de Cancerologie de l’Ouest, Hospital Clinic de Barcelona, Istituto Oncologico Veneto, Centre Leon Berard, and Universitaetsklinikum Essen.
The leading sites are not small single-study participants; they are recurring prostate cancer trial infrastructure nodes. Spain and France dominate the top of the list, while Italy and Germany add specialist oncology, urology, nuclear medicine, and radiotherapy capacity.
The top 10 recurring sites are distributed across four countries: Spain contributes 3/10 sites, France contributes 4/10, Italy contributes 2/10, and Germany contributes 1/10. Together, Spain and France represent 7/10 leading recurring sites, or 70.0% of the top-site network.
The country pattern is concentrated but not single-country dependent. Spain and France provide the densest recurring site layer, while Italy and Germany appear as important specialist contributors, especially for prostate oncology and nuclear medicine–linked programs.
Phase III is more concentrated in 2024 than Phase II. Among 64 Phase III records, 46 were from 2024, representing 71.9%; among 59 Phase II records, 30 were from 2024, representing 50.8%. Phase II had a larger 2025 share than Phase III: 24/59 records, or 40.7%, versus 14/64 records, or 21.9%.
| Phase | 2024 | 2025 | 2026 | Total |
|---|---|---|---|---|
| Phase II | 30 | 24 | 5 | 59 |
| Phase III | 46 | 14 | 4 | 64 |
Phase III activity is more front-loaded into 2024, while Phase II remains more evenly spread into 2025. This pattern is consistent with a field where mature registration programs coexist with newer expansion programs and modality-specific exploration.
This report uses site-level and geography-level CTIS terminology. A site appearance means a named clinical site listed in a trial geography record. A geography record means one extracted trial geography entry from the prostate cancer Phase II/III cohort.